menu
    • menu

    Company profile for Palatin Technologies

    NEW Drugs in Dev: 7
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Vyleesi™, the trade name for Br...
    Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Vyleesi™, the trade name for Bremelanotide, for the treatment of hypoactive sexual desire disorder (HSDD) is our lead product. A New Drug Application for approval of Vyleesi was approved by the Food and Drug Administration (FDA) in June 2019.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Palatin TechnologiesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4-B Cedar Brook Drive Cedar Brook Corporate Center Cranbury, NJ 08512
    Telephone
    Telephone
    1-609-495-2200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://palatin.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Palatin Reveals Q2 Fy2026 Financials And Corporate Progress
    Palatin Reveals Q2 Fy2026 Financials And Corporate Progress

    17 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update-302688156.html

    PR NEWSWIRE
    17 Feb 2026
    Share Share
    Palatin Reveals Q1 Fy2026 Financials And Corporate Progress
    Palatin Reveals Q1 Fy2026 Financials And Corporate Progress

    13 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-reports-first-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update-302614162.html

    PR NEWSWIRE
    13 Nov 2025
    Share Share
    Palatin Technologies Closes $18.2M Upsized Offering
    Palatin Technologies Closes $18.2M Upsized Offering

    12 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-technologies-announces-closing-of-upsized-18-2-million-public-offering-with-the-full-exercise-of-the-underwriters-over-allotment-option-302613372.html

    PR NEWSWIRE
    12 Nov 2025
    Share Share
    Palatin Pharma Sets $15.8M Public Offering Price
    Palatin Pharma Sets $15.8M Public Offering Price

    06 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-technologies-announces-pricing-of-upsized-15-8-million-public-offering-302606870.html

    PR NEWSWIRE
    06 Nov 2025
    Share Share
    Palatin Unveils Melanocortin Therapy Data at ENDO 2025
    Palatin Unveils Melanocortin Therapy Data at ENDO 2025

    06 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-presents-data-at-obesityweek-2025-highlighting-promise-of-melanocortin-based-therapies-for-obesity-302606887.html

    PR NEWSWIRE
    06 Nov 2025
    Share Share
    Palatin Gets €5.5M Milestone In Retinal Deal With Boehringer
    Palatin Gets €5.5M Milestone In Retinal Deal With Boehringer

    22 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-earns-5-5-million-6-5-million-milestone-payment-in-retinal-disease-collaboration-with-boehringer-ingelheim-302562035.html

    PR NEWSWIRE
    22 Sep 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search